Andersons pediatric cardiology 2121
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.63 KB, 3 trang )
S.Dietonlyanddietplussimvastatininthe
treatmentofheterozygousfamilial
hypercholesterolemiainchildhood.DrugsExp
ClinRes.1999;25(1):23–28.
74.Garcia-de-la-PuenteS,Arredondo-GarciaJL,
Gutierrez-CastrellonP,etal.Efficacyof
simvastatininchildrenwithhyperlipidemia
secondarytokidneydisorders.PediatrNephrol.
2009;24(6):1205–1210.
75.KameyamaY,YamashitaK,KobayashiK,
HosokawaM,ChibaK.Functional
characterizationofSLCO1B1(OATP-C)
variants,SLCO1B1*5,SLCO1B1*15and
SLCO1B1*15+c1007g,byusingtransient
expressionsystemsofHeLaandHEK293cells.
PharmacogenetGenomics.2005;15(7):513–522.
76.NiemiM,SchaeffelerE,LangT,etal.High
plasmapravastatinconcentrationsareassociated
withsinglenucleotidepolymorphismsand
haplotypesoforganicaniontransporting
polypeptide-C(OATP-C,SLCO1B1).
Pharmacogenetics.2004;14(7):429–440.
77.PasanenMK,NeuvonenM,NeuvonenPJ,Niemi
M.SLCO1B1polymorphismmarkedlyaffects
thepharmacokineticsofsimvastatinacid.
PharmacogenetGenomics.2006;16(12):873–
879.
78.VooraD,ShahSH,SpasojevicI,etal.The
SLCO1B1*5geneticvariantisassociatedwith
statin-inducedsideeffects.JAmCollCardiol.
2009;54(17):1609–1616.
79.GroupSC,LinkE,ParishS,etal.SLCO1B1
variantsandstatin-inducedmyopathy–a
genomewidestudy.NEnglJMed.
2008;359(8):789–799.
80.Tachibana-IimoriR,TabaraY,KusuharaH,etal.
EffectofgeneticpolymorphismofOATP-C
(SLCO1B1)onlipid-loweringresponseto
HMG-CoAreductaseinhibitors.DrugMetab
Pharmacokinet.2004;19(5):375–380.
81.LiJH,SuchindranS,ShahSH,etal.SLCO1B1
geneticvariants,long-termlow-density
lipoproteincholesterollevelsandclinicalevents
inpatientsfollowingcardiaccatheterization.
Pharmacogenomics.2015;16(5):449–458.
82.DaiR,FengJ,WangY,etal.Association
betweenSLCO1B1521TCand388AG
polymorphismsandstatinseffectiveness:a
Meta-analysis.JAtherosclerThromb.
2015;22(8):796–815.
83.ThompsonJF,ManM,JohnsonKJ,etal.An
associationstudyof43SNPsin16candidate
geneswithatorvastatinresponse.
PharmacogenomicsJ.2005;5(6):352–358.
84.RamseyLB,JohnsonSG,CaudleKE,etal.The
clinicalpharmacogeneticsimplementation
consortiumguidelineforSLCO1B1and
simvastatin-inducedmyopathy:2014update.
ClinPharmacolTher.2014;96(4):423–428.
85.WagnerJB,Abdel-RahmanS,VanHaandelL,et
al.ImpactofSLCO1B1GenotypeonPediatric
SimvastatinAcidPharmacokinetics.JClin
Pharmacol.2018;58(6):823–833.
86.WagnerJ,VanHaandelL,RaghuveerG,etal.
Pharmacokineticsofpravastatininpediatric
dyslipidemia:clinicalimpactofgeneticvariation
onstatindisposition.Circulation.
2015;132(suppl):A13716[Abstract].
87.TillJA,ShinebourneEA,RowlandE,etal.
Paediatricuseofflecainideinsupraventricular
tachycardia:clinicalefficacyand
pharmacokinetics.BrHeartJ.1989;62(2):133–
139.
88.ZeiglerV,GillettePC,RossBA,EwingL.
Flecainideforsupraventricularandventricular
arrhythmiasinchildrenandyoungadults.AmJ
Cardiol.1988;62(10Pt1):818–820.
89.Flecainideversusquinidinefortreatmentof
chronicventriculararrhythmias.Amulticenter
clinicaltrial.Circulation.1983;67(5):1117–
1123.
